Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.

Gut · 2015 · PMC4680183 · PMID 25429050

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Both mesalazine and TQ showed a tumour reduction from 39% in untreated mice to 21% (p=0.19; RR: 0.53, 95% CI 0.23 to 1.23) and to 31% (p=0.56; RR: 0.79, 95% CI 0.38 to 1.67), respectively, which did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.